Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia
Open Access
- 28 April 2020
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (8), 1670-1677
- https://doi.org/10.1182/bloodadvances.2019001156
Abstract
Circulating cell-free DNA (ccfDNA) allows for noninvasive peripheral blood sampling of cancer-associated mutations and has established clinical utility in several solid tumors. We performed targeted next-generation sequencing of ccfDNA and bone marrow at the time of diagnosis and after achieving remission in 22 patients with acute myeloid leukemia (AML). Among 28 genes sequenced by both platforms, a total of 39 unique somatic mutations were detected. Five mutations (13%) were detected only in ccfDNA, and 15 (38%) were detected only in bone marrow. Among the 19 mutations detected in both sources, the concordance of variant allelic frequency (VAF) assessment by both methods was high (R-2 = 0.849). Mutations detected in only 1 source generally had lower VAF than those detected in both sources, suggesting that either method may miss small subclonal populations. In 3 patients, sequencing of ccfDNA detected new or persistent leukemia-associated mutations during remission that appeared to herald overt relapse. Overall, this study demonstrates that sequencing of ccfDNA in patients with AML can identify clinically relevant mutations not detected in the bone marrow and may play a role in the assessment of measurable residual disease. However, mutations were missed by both ccfDNA and bone marrow analyses, particularly when the VAF was <10%, suggesting that ccfDNA and bone marrow may be complementary in the assessment and monitoring of patients with AML.This publication has 24 references indexed in Scilit:
- Deep Sequencing of Cell-Free Peripheral Blood DNA as a Reliable Method for Confirming the Diagnosis of Myelodysplastic SyndromeGenetic Testing and Molecular Biomarkers, 2016
- Assessment of Minimal Residual Disease in Standard-Risk AMLThe New England Journal of Medicine, 2016
- Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemiaLeukemia, 2015
- Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid LeukemiaJAMA, 2015
- Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic SyndromesTransplantation and Cellular Therapy, 2015
- Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker studyThe Lancet Oncology, 2015
- Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoringHaematologica, 2013
- Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trialBlood, 2012
- Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrowHaematologica, 2007
- Prediction of Breast Tumor Progression by Integrity of Free Circulating DNA in SerumJournal of Clinical Oncology, 2006